Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 TrialAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
The Lancet. Haematology|November 1, 2023
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialMichael Lübbert, Pierre W Wijermans, Michal Kicinski, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Corneel Coens, Justyna Mierzynska, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Biologic and clinical features of childhood gamma delta T-ALL: identification of STAG2/LMO2 γδ T-ALL as an extremely high risk leukemia in the very youngShunsuke Kimura, Petri Polonen, Lindsey Montefiori, et al.
Cancer Discovery|June 25, 2024
Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High RiskShunsuke Kimura, Chun Shik Park, Lindsey E Montefiori, et al.
Pageof 5